(1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester | 1034079-38-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester
• 英文别名: (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-exo-carboxylic acid ethyl ester；(1R,2S,4S)-ethyl 7-oxabicyclo[2.2.1]heptane-2-carboxylate；ethyl (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxylate
• CAS: 1034079-38-3
• 化学式: C₉H₁₄O₃
• 分子量: 170.208
• InChiKey: XXCACDZPLZGDIH-BIIVOSGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 在 lipase A from candida antarctica 、 水 作用下， 反应 72.0h， 生成 (1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-exo-carboxylic acid
  参考文献：
  名称：

  Enantioselective synthesis of (1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-exo-carboxylic acid

  摘要：

  A scalable enantioselective access to (1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-exo-carboxylic acid 7, a key precursor in the synthesis of A2a receptor antagonist 1 by means of an enzymatic resolution of the respective butyl ester with lipase A from Candida antarctica, is described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.12.030
• 作为产物：
  描述：

  乙醇 、 (1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-exo-carboxylic acid 在 硫酸 作用下， 以 水 为溶剂， 生成 (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES

  摘要：

  本发明涉及一种制备式I的7-氧杂双环衍生物的方法。

  公开号：

  US20080154043A1

文献信息

• HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS
  申请人：Schnute Mark E.

  公开号：US20110009435A1

  公开（公告）日：2011-01-13

  The present invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.

  本发明涉及公式I化合物及其药学上可接受的盐、制备该化合物的方法、制备中间体以及含有该化合物的组合物和该化合物作为抗炎药物的用途。
• Adaptation of an Exothermic and Acylazide-Involving Synthesis Sequence to Microreactor Technology
  作者：Luigi Rumi、Christophe Pfleger、Paul Spurr、Uwe Klinkhammer、Willi Bannwarth

  DOI：10.1021/op9000516

  日期：2009.7.17

  The original three-step batchwise synthesis of the pharmaceutical intermediate (IR,2S,4S)-(7-oxa-bicyclo[2.2.1]hept-2-yl)-carbamic acid ethyl ester (4) from (1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carboxyolic acid ethyl ester (1) encompassed a highly exothermic hydrazine quenching step as well as an acylazide intermediate. After appropriately modifying the reaction conditions, all three steps could be adapted to a microreactor system and a continuous process which permitted the desired carbamate 4 to be prepared under safe operating conditions in yields of 96%, 94%, and 84% for the three individual steps.
• [EN] PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES<br/>[FR] PROCÉDÉ DE FABRICATION DE DÉRIVÉS 7-OXA-BICYCLO
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008077809A1

  公开（公告）日：2008-07-03

  [EN] The present invention relates to a process for the manufacture of the 7-oxabicyclo derivative of the formula (I).
  [FR] La présente invention porte sur un procédé de fabrication du dérivé 7-oxabicyclo de la formule (I).
• [EN] HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS<br/>[FR] DÉRIVÉS CARBOXAMIDES HÉTÉRO-BICYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE ET COMPOSITIONS
  申请人：PFIZER

  公开号：WO2008149191A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to compounds of Formula (I)I and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.
  [FR] La présente invention concerne des composés représentés par la formule (I)I et des sels pharmaceutiquement acceptables de ceux-ci, des procédés de préparation desdits composés, des intermédiaires utilisés pour leur préparation et des compositions les contenant, ainsi que l'utilisation desdits composés en tant qu'agents anti-inflammatoires.